LifeSource is directly linked to TCA Cellular Therapy, a research and development company initiating new regenerative medicine therapies.  The invention of a unique combination stem cell therapy represents a substantial promise as a cellular agent for cardiovascular and severe limb ischemia.  The protocols have been released by the FDA to begin Phase I research studies in these two fields. This gives our company a leading edge in the regenerative medicine field.  The combination stem cell therapy may also be applied to other applications that we are currently developing.

Our trials use autologous stem cell therapy which means that a subject uses his/her own stem cells for the therapy and not someone else’s.

Current Phase I clinical trials being conducted are:

• Autologous Bone Marrow - derived stem cells for repair of infarcted myocardium in patients during bypass surgery.
• Autologous Bone Marrow - derived stem cells for rescue and repair in acute myocardial infarction in patients after angioplasty
• Autologous Bone Marrow - derived stem cells for treatment of limb ischemia

In the Media

TV News:

• WWLTV.com - "Can heart blockage be cured with patient's own stem cells?"
• WWLTV.com - "Dr. breaks new ground by using stem cells on damaged hearts"
• ABC 26 News - "Two North Shore Doctors Making Medical History
  Using Stem Cell Therapy"

Forbes:

• Participants in TCA Cellular Therapy's Stem Cell Protocol Experiencing Remarkable Results

Gambit:

• Health Feature: Cellular Service

National Institute of Health - clinical trials:

• Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium
• Combination Stem Cell Therapy for the Treatment of Severe
  Coronary Ischemia (CI)
• Combination Stem Cell Therapy for the Treatment of Severe
  Leg Ischemia (mesendo)